• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term safety and tolerability of delamanid-containing regimens in multidrug-resistant and extensively drug-resistant tuberculosis patients in a specialised treatment centre in Berlin, Germany.

作者信息

Häcker Brit, Schönfeld Nicolas, Krieger David, Otto-Knapp Ralf, Hittel Norbert, Pflugmacher Patricia, Bauer Torsten

机构信息

Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany

DZK - German Central Committee against tuberculosis (DZK e.V.), Berlin, Germany.

出版信息

Eur Respir J. 2020 Dec 3;56(6). doi: 10.1183/13993003.00009-2020. Print 2020 Dec.

DOI:10.1183/13993003.00009-2020
PMID:32631834
Abstract
摘要

相似文献

1
Long-term safety and tolerability of delamanid-containing regimens in multidrug-resistant and extensively drug-resistant tuberculosis patients in a specialised treatment centre in Berlin, Germany.德国柏林一家专业治疗中心中含地拉曼尼方案对耐多药和广泛耐药结核病患者的长期安全性和耐受性
Eur Respir J. 2020 Dec 3;56(6). doi: 10.1183/13993003.00009-2020. Print 2020 Dec.
2
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.地拉曼尼与贝达喹啉治疗儿童耐多药和广泛耐药结核病：一项系统评价
J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16.
3
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.儿童耐多药和广泛耐药结核病的治疗：贝达喹啉和德拉马尼的作用
Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074.
4
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.在白俄罗斯，2015-2019 年间，含德拉马尼或贝达喹啉方案治疗儿童和青少年耐多药或广泛耐药结核病的疗效和安全性：一项全国性研究。
Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1646.
5
Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.含德拉马尼方案治疗耐多药或广泛耐药结核病成人的疗效和心血管安全性：来自白俄罗斯的 2016-18 年全国性队列研究。
Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1647.
6
Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).地拉米定：从发现到用于治疗肺部耐多药结核病（MDR-TB）。
Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3.
7
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.德拉马尼与贝达喹啉联合用于治疗耐多药和广泛耐药结核病：一项系统评价
Int J Mol Sci. 2017 Feb 7;18(2):341. doi: 10.3390/ijms18020341.
8
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.德拉马尼可改善耐多药结核病的治疗结局，降低死亡率。
Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.
9
Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.当其他抗结核治疗方案因耐药性或耐受性而失败时使用地拉米定。
Expert Opin Pharmacother. 2015 Feb;16(2):253-61. doi: 10.1517/14656566.2015.973853. Epub 2014 Oct 18.
10
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.在德国，将新型或第5组干预措施添加到背景治疗方案中用于治疗耐多药结核病的成本效益。
BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2.

引用本文的文献

1
Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report.全基因组测序在广泛耐药结核病管理中的临床应用：一例报告。
Ann Clin Microbiol Antimicrob. 2024 Aug 22;23(1):76. doi: 10.1186/s12941-024-00737-9.
2
Real-life use of delamanid: results from the European post-authorisation safety study.地拉米韦的实际应用：欧洲上市后安全性研究结果
IJTLD Open. 2024 Jun 1;1(6):274-278. doi: 10.5588/ijtldopen.24.0113. eCollection 2024 Jun.
3
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.
含德拉马尼方案与耐多药结核病：系统评价和荟萃分析。
Int J Infect Dis. 2022 Nov;124 Suppl 1(Suppl 1):S90-S103. doi: 10.1016/j.ijid.2022.02.043. Epub 2022 Mar 2.